Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System

Author:

Sakai Takamasa,Mori Chiyo,Ohtsu Fumiko

Abstract

Objectives: Intraocular administration of vascular endothelial growth factor (VEGF) inhibitors may be associated with pregnancy loss. However, little is known about intraocular anti-VEGF therapy during pregnancy. Here, we conducted a pharmacovigilance study using a spontaneous reporting database to evaluate the relationship between intraocular VEGF inhibitors and pregnancy loss.Methods: We used the JAPIC AERS database which is composed of the Food and Drug Administration Adverse Event Reporting System (FAERS) dataset preprocessed by the Japan Pharmaceutical Information Center (JAPIC) to investigate the VEGF inhibitors ranibizumab, aflibercept, and bevacizumab. Disproportionality analyses were conducted for VEGF inhibitors and pregnancy loss. The lower limit of the 95% confidence interval (CI) of the reporting odds ratio (ROR) > 1 and a minimum of three reported cases of pregnancy loss were the detection criteria used in the current study.Results: In the FAERS, 19 pregnancy loss cases were reported for ranibizumab with an ROR of 4.44 (95% CI: 2.42–8.16), 6 for intraocular bevacizumab with an ROR of 32.25 (95% CI: 3.88–267.9), and 4 for intraocular aflibercept with an ROR of 5.37 (95% CI: 1.34–21.49). All these drugs met the detection criteria.Conclusion: Potential safety signals of pregnancy loss were obtained from intraocular administration of VEGF inhibitors during pregnancy. These signals should be validated using a causal design study.

Funder

Japan Society for the Promotion of Science

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference33 articles.

1. Early miscarriage occurring six days after intravitreal ranibizumab injection;Akkaya;Med. Hypothesis Discov. Innov. Ophthalmol.,2019

2. Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage;Almawi;Hum. Reprod.,2013

3. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD;Avery;Br. J. Ophthalmol.,2014

4. VEGF-directed blood vessel patterning: From cells to organism;Bautch;Cold Spring Harb. Perspect. Med.,2012

5. Safety of direct oral anticoagulant exposure during pregnancy: A retrospective cohort study;Beyer-Westendorf;Lancet. Haematol.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3